Pyridostigmine
Pyridostigmine bromide is a synthetic quaternary ammonium anticholinesterase agent primarily used in veterinary medicine for the management of **myasthenia gravis (MG)** in dogs, and less commonly in cats. * **Clinical Pearl:** Because of its quaternary ammonium structure, pyridostigmine is highly ionized and does not readily cross the blood-brain barrier at standard therapeutic doses. This makes it ideal for targeting peripheral neuromuscular junction disorders like MG without causing significant central nervous system (CNS) side effects. * It is generally considered much more effective for **acquired myasthenia gravis** compared to the congenital form of the disease. * Due to its erratic absorption and narrow therapeutic index, dosing must be carefully titrated to effect, balancing improved muscle strength against the risk of cholinergic toxicity.
Mecanismo: **Pyridostigmine** acts as a reversible, competitive inhibitor of the enzyme **acetylcholinesterase (AChE)** at the neuromuscular junction. * **Mechanism:** Pyridostigmine competes directly with **acetylcholine (ACh)** for attachment to AChE. The resulting pyridostigmine-AChE complex is hydrolyzed much more slowly than the natural ACh-AChE complex. * **Pathway:** Inhibition of AChE → Decreased breakdown of ACh → Accumulation of ACh in the synaptic cleft → Prolonged and increased stimulation of **nicotinic ACh receptors** on the motor endplate → Enhanced skeletal muscle contraction and improved strength in myasthenic patients.
Dosificación por especie
- Myasthenia gravis (MG) · 0.5-3 mg/kg daily PO in divided doses · PO · Divided daily · Dose depending on response.
- Myasthenia gravis (MG) · 1-3 mg/kg PO q8-12h · PO · q8-12h
- Myasthenia gravis (MG) · 0.5-3 mg/kg PO per day · PO · Daily · Given with corticosteroids.
- Myasthenia gravis · 0.25 mg/kg · PO · q8-12h
- Myasthenia gravis (MG) · 1-3 mg/kg PO q8-12h. For animals that cannot tolerate oral medications, it may be used as an IV constant rate infusion at 0.01-0.03 mg/kg/hour. · PO/IV · q8-12h or CRI · Titrate to effect to minimize adverse effects and maximize muscle strength.
- Myasthenia gravis (MG) · 0.5-3 mg/kg PO q8-12 hours with food. · PO · q8-12h · Start low and increase slowly. Liquid formulation recommended for easy adjustment. An H2 antagonist (e.g., famotidine 5 mg/kg/day) may reduce nausea/GI irritation.
- Acquired Myasthenia gravis (MG) · 7.5-30 mg PO two times a day. · PO · BID · Begin after oral regurgitation is abolished with parenteral neostigmine. Once stable, begin corticosteroids for 2 weeks, then gradually reduce pyridostigmine.
- Myasthenia gravis (MG) · 0.5-3 mg/kg PO two to three times a day. · PO · BID-TID · If no response, add prednisone.
- Myasthenia gravis (MG) · 0.5-1 mg/kg PO two to three times a day · PO · BID-TID · With or without prednisone (2 mg/kg PO twice daily). Spontaneous remission is not uncommon.
Vías de administración
Contraindicaciones
- Hypersensitivity to anticholinesterase compounds or bromides
- Mechanical or physical obstructions of the urinary tract
- Mechanical or physical obstructions of the gastrointestinal (GI) tract
- Mechanical gastrointestinal obstruction
- Mechanical urinary tract obstruction
- Peritonitis
Efectos adversos
- Nausea
- Vomiting
- Diarrhea
- Excessive salivation (ptyalism)
- Sweating (in species with sweat glands)
- Increased bronchial secretions
- Bronchospasm
- Pulmonary edema
- Respiratory paralysis
- Miosis (pupil constriction)
- Blurred vision
- Lacrimation (tearing)
- Bradycardia
- Tachycardia
- Cardiospasm
- Hypotension
- Cardiac arrest
Interacciones farmacológicas
- Atropine · Antagonizes the muscarinic effects of pyridostigmine. Use cautiously as it can mask early clinical signs of a life-threatening cholinergic crisis.
- Corticosteroids · May decrease the anticholinesterase activity of pyridostigmine. Discontinuing corticosteroids may suddenly increase anticholinesterase activity, requiring dose adjustments.
- Dexpanthenol · Theoretically may have additive cholinergic effects when used concurrently.
- Neuromuscular blocking drugs (e.g., aminoglycosides) · May necessitate increased dosages of pyridostigmine when treating or diagnosing myasthenic patients.
- Magnesium (parenteral) · Can antagonize anticholinesterase therapy due to its direct depressant effect on skeletal muscle.
- Muscle Relaxants · May prolong the Phase I block of depolarizing muscle relaxants (e.g., succinylcholine) and antagonize the actions of non-depolarizing agents (e.g., pancuronium, atracurium).
- Aminoglycosides · May antagonize the neuromuscular effects of pyridostigmine · moderate
- Clindamycin · May antagonize the neuromuscular effects of pyridostigmine · moderate
- Lincomycin · May antagonize the neuromuscular effects of pyridostigmine · moderate
- Propranolol · May antagonize the effects of pyridostigmine · moderate
- Suxamethonium · Pyridostigmine may enhance the effect of depolarizing muscle relaxants · major
Monitorización
- Clinical signs of cholinergic toxicity (salivation, lacrimation, urination, defecation, GI upset, emesis, weakness)
- Efficacy of therapy (improvement in muscle strength, reduction of megaesophagus/regurgitation)
- Respiratory rate and effort
- Improvement in muscle strength and exercise tolerance
- Signs of muscarinic toxicity (hypersalivation, vomiting, diarrhea, miosis)
- Heart rate and rhythm
- Respiratory rate and effort (especially in patients with megaoesophagus)
Sobredosis
Overdosage of pyridostigmine can induce a life-threatening **cholinergic crisis**. * **Clinical Signs (SLUDGE syndrome):** GI effects (nausea, vomiting, diarrhea), excessive salivation, sweating, respiratory distress (increased bronchial secretions, bronchospasm, pulmonary edema, respiratory paralysis), ophthalmic effects (miosis, blurred vision, lacrimation), cardiovascular collapse (bradycardia, tachycardia, hypotension, cardiac arrest), severe muscle cramps, and profound weakness. * **Diagnostic Challenge:** Overdoses in myasthenic patients can be very difficult to distinguish from a **myasthenic crisis** (disease exacerbation). The time of onset of clinical signs or an **edrophonium challenge** (Tensilon test) may help differentiate the two. * **Treatment:** Consists of immediate respiratory and cardiac supportive therapy. **Atropine** should be administered to antagonize muscarinic effects (refer to atropine protocols for cholinergic toxicity).
La referencia de fármacos de VetSheet está destinada a veterinarios colegiados como apoyo a la decisión clínica, no sustituye el juicio profesional ni la ficha técnica vigente del fabricante.